Rapid Micro Biosystems, Inc.

RAPID MICRO BIOSYSTEMS, INC. is an innovative life sciences technology company that provides critical automation solutions for pharmaceutical manufacturing. The company focuses on transforming microbial quality control (MQC) within pharmaceutical production through fully automated systems. Its products are designed to protect complex bioprocessing workflows, leading to faster, safer, and higher capacity drug production. The company's flagship product is the Growth Direct platform, which automates and modernizes manual MQC testing workflows used in large pharmaceutical manufacturing operations globally. This platform aims to bring quality control to the manufacturing floor, offering faster results, greater accuracy, increased operational efficiency, improved compliance with data integrity regulations, and quicker decision-making for customers. The Growth Direct platform is described as the only fully automated, high-throughput, and secure MQC solution, developed with over 15 years of customer feedback. It addresses MQC challenges related to the increasing scale, complexity, and regulatory scrutiny faced by global pharmaceutical manufacturers. The platform provides robust and scalable automation to support the growing demand for therapeutic modalities such as biologics, cell and gene therapies, vaccines, and sterile injectables. The systems are designed to automate most daily MQC test volume in pharmaceutical manufacturing facilities and can be operated in networked fleets of multiple systems per facility or campus to scale with high-volume manufacturing.